Monday, October 24, 2016

Boots Sore Mouth Gel





1. Name Of The Medicinal Product



Sore Mouth Gel


2. Qualitative And Quantitative Composition










Active ingredients




Quantity % w/w



Lidocaine base


0.6




Cetylpyridinium chloride




0.02



3. Pharmaceutical Form



Oromucosal Gel



4. Clinical Particulars



4.1 Therapeutic Indications



For the rapid relief of pain caused by minor recurrent aphthous mouth ulcers.



4.2 Posology And Method Of Administration



For topical application to the mouth and gums.



Adults and children



A small quantity of gel to be applied to the sore area with a clean finger every three hours as necessary.



Babies



Not suitable.



4.3 Contraindications



Patients hypersensitive to any of the ingredients.



4.4 Special Warnings And Precautions For Use



Keep all medicines out of the reach of children.



If symptoms persist for more than seven days consult your doctor or dentist.



Sore Mouth Gel is not suitable for the treatment of teething troubles in babies.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



No clinically significant drug interactions known.



4.6 Pregnancy And Lactation



The safety of Sore Mouth Gel during pregnancy and lactation has not been established but is not considered to constitute a hazard.



4.7 Effects On Ability To Drive And Use Machines



No adverse effects known.



4.8 Undesirable Effects



Hypersensitivity reactions due to lidocaine have been reported rarely and to cetylpyridinium chloride occasionally.



4.9 Overdose



Overdosage with Sore Mouth Gel is unlikely to constitute a hazard and therefore symptomatic treatment only is necessary.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Lidocaine is a local anaesthetic of the amide type. Cetylpyridinium chloride is a cationic antiseptic.



5.2 Pharmacokinetic Properties



Lidocaine is rapidly absorbed from mucous membranes. The plasma elimination half life is about two hours.



Lidocaine undergoes significant first pass metabolism in the liver and is rapidly de-ethylated to the active metabolite monoethylglycinexylidide and then hydrolysed to various metabolites including glycinexylidide. Less than 10% is excreted unchanged by the kidneys. The metabolites are also excreted in the urine.



5.3 Preclinical Safety Data



Not applicable.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Refined sugar



Cetomacrogol 1000



Hypromellose



Alcohol 96%



Eucalyptol



Levomenthol synthetic or natural



Star anise oil



Purified water



6.2 Incompatibilities



None stated.



6.3 Shelf Life



36 months.



6.4 Special Precautions For Storage



Store below 25°C.



6.5 Nature And Contents Of Container



A collapsible aluminium tube, internally lacquered with a polyamide/polyimide lacquer system with a membrane seal fitted with a wadless polythene cap or polypropylene cap.



Pack size: 15 gm.



6.6 Special Precautions For Disposal And Other Handling



None stated.



7. Marketing Authorisation Holder



The Boots Company PLC



1 Thane Road West



Nottingham NG2 3AA



8. Marketing Authorisation Number(S)



PL 0014/0150



9. Date Of First Authorisation/Renewal Of The Authorisation



Date of First Authorisation: 25 June 1974



Date of Last Renewal: 16 April 2004



10. Date Of Revision Of The Text



July 2005





No comments:

Post a Comment